Journal of Medicinal Chemistry p. 1086 - 1097 (2018)
Update date:2022-08-04
Topics:
Piotrowski, David W.
Futatsugi, Kentaro
Casimiro-Garcia, Agustin
Wei, Liuqing
Sammons, Matthew F.
Herr, Michael
Jiao, Wenhua
Lavergne, Sophie Y.
Coffey, Steven B.
Wright, Stephen W.
Song, Kun
Loria, Paula M.
Banker, Mary Ellen
Petersen, Donna N.
Bauman, Jonathan
A novel series of morpholine-based nonsteroidal mineralocorticoid receptor antagonists is reported. Starting from a pyrrolidine HTS hit 9 that possessed modest potency but excellect selectivity versus related nuclear hormone receptors, a series of libraries led to identification of morpholine lead 10. After further optimization, cis disubstituted morpholine 22 was discovered, which showed a 45-fold boost in binding affinity and corresponding functional potency compared to 13. While 22 had high clearance in rat, it provided sufficient exposure at high doses to favorably assess in vivo efficacy (increased urinary Na+/K+ ratio) and safety. In contrast to rat, the dog and human MetID and PK profiles of 22 were adequate, suggesting that it could be suitable as a potential clinical asset.
View MoreContact:21-7631221 15884421033
Address:326 Science and technology,Shanghai,China
Hangzhou Share Chemical Co., Ltd(expird)
Contact:+86-57187093700
Address:Hang Xing Road
LianYunGang Chiral Chemical(CHINA) CO.,LTD
Contact:+86-518-83616958 +86-519-82884848
Address:LianYunGang Chemical Industry Park (JiangSu)
Contact:Tel:+86-29-88764861 Fax:+86-29-88764861
Address:Rm#2107, Block A, Epin Meidao Building, Gaoxin Rd, Hi-Tech Zone, Xi’an, China
jiangsu senxuan pharmaceutical and chemical co.,ltd
Contact:86-523-87982810
Address:hongqiao industrial zone,taixing,jiangsu china
Doi:10.1016/0022-328X(91)86057-W
(1991)Doi:10.1039/c2ob06942c
(2012)Doi:10.1016/0022-328X(91)80062-O
(1991)Doi:10.1016/j.poly.2012.02.024
(2012)Doi:10.1002/anie.201109130
(2012)Doi:10.1007/s10600-012-0212-6
(2012)